These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17538986)

  • 1. New drugs: kids come first; con: first adults, then children.
    Murphy MS
    Inflamm Bowel Dis; 2007 Sep; 13(9):1170-5; discussion 1176-7. PubMed ID: 17538986
    [No Abstract]   [Full Text] [Related]  

  • 2. "New drugs: kids come first": children should be included in trials of new biological treatments.
    Cucchiara S; Morley-Fletcher A
    Inflamm Bowel Dis; 2007 Sep; 13(9):1165-9; discussion 1176-7. PubMed ID: 17455208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inflammatory bowel disease: an overview].
    Herrlinger K
    Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases.
    Ghosh S; Sandborn WJ; Colombel JF; Feagan BG; Panaccione R; Hanauer S; Schreiber S; Peyrin-Biroulet L; Vermeire S; Eichner S; Huang B; Robinson AM; Pappalardo B
    Inflamm Bowel Dis; 2016 Nov; 22(11):2711-2723. PubMed ID: 27585411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory bowel disease in general practice.
    Moreea S; Kelly SM
    Practitioner; 2004 May; 248(1658):344-6, 348, 350 passim. PubMed ID: 15160476
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biological therapies in inflammatory bowel disease].
    Ricart E
    Gastroenterol Hepatol; 2003 Mar; 26(3):161-2. PubMed ID: 12586011
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in Pediatric Inflammatory Bowel Disease.
    Maxwell EC; Grossman AB
    Adolesc Med State Art Rev; 2016; 27(1):57-74. PubMed ID: 27363233
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current concepts about the treatment of inflammatory bowel disease, biological therapy].
    Bosques-Padilla FJ; Galindo-Marines SL; Yamamoto-Farusho JK
    Rev Gastroenterol Mex; 2008; 73(4):217-30. PubMed ID: 19666271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 12. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
    [No Abstract]   [Full Text] [Related]  

  • 13. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    Peyrin-Biroulet L
    Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
    [No Abstract]   [Full Text] [Related]  

  • 14. [Granulocyte-monocyte apheresis for the treatment of inflammatory bowel disease].
    ; Passalacqua S; Ferraro PM
    G Ital Nefrol; 2012; 29 Suppl 54():S61-3. PubMed ID: 22388832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early or late guided missile in the treatment of Crohn's disease?
    Caprilli R; Angelucci E; Cocco A
    Dig Liver Dis; 2005 Dec; 37(12):973-9. PubMed ID: 16169305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases.
    Schreiber S; Vermeire S
    Gastroenterology; 2016 May; 150(5):1061-1066. PubMed ID: 27018485
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of inflammatory bowel disease: past, present and future.
    Keyashian K; Annunziata ML; Sakuraba A; Hanauer S
    Expert Rev Clin Immunol; 2012 May; 8(4):303-5. PubMed ID: 22607175
    [No Abstract]   [Full Text] [Related]  

  • 19. The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials.
    Peyrin-Biroulet L; Gower-Rousseau C
    J Crohns Colitis; 2016 Dec; 10(12):1375-1377. PubMed ID: 27664272
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the medical management of paediatric IBD.
    Aloi M; Nuti F; Stronati L; Cucchiara S
    Nat Rev Gastroenterol Hepatol; 2014 Feb; 11(2):99-108. PubMed ID: 23958601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.